MeTA Process and Progress in Jordan

Loading...

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

0 comments

Post a comment

    Post a comment
    Embed Video
    Edit your comment Cancel

    Notes on slide 1

    Title of presentation 10/06/09 MeTA

    Favorites, Groups & Events

    MeTA Process and Progress in Jordan - Presentation Transcript

    1. Rania Bader MeTA Consultant MeTA Process and Progress in Jordan MeTA 10/06/09
    2. Jordan’s Fact Sheet
      • Population: 5.8 million
      • Health expenditure: 10.4 % of GDP
      • (30% of this spent on medicines)
      • Total Medicine Expenditure $ 338 Million
      • Public Medicine Expenditure $ 112.6 Million
      • 25% Medicine expenditure (public sector)
      • 75 % Medicine expenditure (private sector)
      • Local medicines manufacturers: 16
      • Medicines expenditure growth 17% per
      • annum compared to GDP growth of 3.3%
      10/06/09 MeTA
    3. What is MeTA?
      • MeTA brings together at the international and national levels, a diverse group of people working in the pharmaceutical sector through a ( multi-stakeholders approach ) to find ways to improve/increase transparency and accountability in selection, regulation, procurement, distribution and use of medicines in countries
      • MeTA partners are the UK Department for International Development ( DFID ) , the WHO and the World Bank (WB)
      10/06/09 MeTA
    4. Agenda
      • A. MeTA Process in Jordan
      • B. MeTA Progress in Jordan ( achievements so far)
      • C. Monitoring and Evaluation
      • D. Challenges
      • E. Key Successes
      • F. Getting more information
      10/06/09 MeTA
    5. MeTA Process in Jordan:
      • It started with scoping visits
      • Looked into reasons for Jordan to be one of the MeTA pilot Countries
      • Proposal was sent to the Government
      • The Government approved
      • Formed the MeTA Council / stakeholder
      • Drafting Jordan’s Workplan
      • MOU signed
      10/06/09 MeTA
      • MeTA in Jordan
      10/06/09 MeTA
    6. MeTA Process in Jordan:
      • The Minister of Health sent an official letter to MOPIC approving on having the High Health Council (HHC) hosting the MeTA Secretariat
      10/06/09 MeTA
    7. MeTA Process in Jordan:
      • Jordan’s MeTA Council held its first meeting at the HHC in August 2008 after the MeTA council was formed and endorsed by the MOH, the council representation is from the Government, private sector, civil society organizations, professional organizations, and the academia. In addition non- voting representatives from the World Bank (WB), the World Health Organization (WHO) and Health Action international (HAI), with the presence of the MeTA national consultant in Jordan
      10/06/09 MeTA
    8. MeTA Process in Jordan:
      • T he Council serves as the highest policy making and consultative body
      • The council elected his chairperson Dr Taher AbuElSamen and also nominated him to participate as Jordan’s representative on the MeTA International Advisory Group (MIAG) in London every year
      10/06/09 MeTA
    9. MeTA Process in Jordan:
      • The MeTA Council drafted the internal rules and formed Three Committees then developed activities for the areas of work that they chose and included them in the Jordan MeTA workplan
      • Jordan MeTA workplan has been sent officially to the MMB on the 9 th of February 2009 for approval, and it was approved after 7 working days, MOU was signed accordingly
      10/06/09 MeTA
    10. MeTA Process in Jordan:
      • The three committees that have been formed out of the MeTA Council are:
      • 1- Evidence Based Decision Making for the RDL Committee
      • 2- Encouraging Best Practice and Promote Rational Drug Use Committee
      • 3- Civil Society organizations Building Capacity Committee
      10/06/09 MeTA
    11. MeTA Progress in Jordan
      • Supply Chain Mapping
      • Private Sector Mapping
      • CSO Mapping
      • NICE Training on Using Health Technology Assessment to inform decision-making in healthcare
      • MeTA Chair has Participated in the MIAG meeting
      • Held an important session on medicines and transparency at the WHA
      10/06/09 MeTA
    12. WHA 62 Geneva 2009
      • MeTA Jordan held an important session on medicines and transparency and Good Governance at the WHA, Geneva, on19th May. Over 80 participants from the WHA attended with representatives from over 20 different countries including Iraq, Libia,Ghana, Cameroon, Peru, Argentina, India, and Bangladesh
      • Members of the MeTA Jordan Council presented the work they have done so far in setting up a multi-stakeholder group comprising representatives from Government, the pharmaceutical industry, and civil society organizations
      10/06/09 MeTA
    13. Monitoring and Evaluation
          • Monthly progress reports of three working committees and MeTA Jordan Secretariat
          • Quarterly reports by MeTA Council to International MeTA Secretariat Reports will be published on national & international MeTA websites
          • Financial reporting by national MeTA Secretariat
          • External monitor from another MeTA pilot country on annual and also the CSO Alliance could be involved in the monitoring and evaluation process
      10/06/09 MeTA
    14. Challenges
      • Assuring commitment & engagement of ALL stakeholders
      • Clarity and understanding of MeTA’s objectives to Jordan’s MeTA Council stakeholders at ALL levels of their organisations
      • Lack of good quality information and data
      • Civil Society are in early stages of development
      • How to make the MeTA approach SUSTAINABLE
      • The concept behind MeTA processes to be country-led, that in a way caused the process in Jordan to be slower
      10/06/09 MeTA
    15. Key Successes
      • The full support from the Jordanian government, MOH and MOPIC
      • The full support from the international MeTA Secretariat
      • WHO Jordan Country Representative was very supportive
      10/06/09 MeTA
    16. Key Successes
      • DFID, WHO/HQ, WB and WHO/EMRO regional office were very supportive
      • Cooperation between all stakeholders including the private sector and the Council members from all sectors were highly committed to moving the MeTA process forward
      10/06/09 MeTA
    17. References for getting more Information:
      • http://www.medicinestransparency.org/meta-countries/jordan/
      • http://www.haiweb.org/medicineprices/surveys/200405JO/survey_report.pdf
      • http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHA-Briefing-note.pdf
      • http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHA-MeTA-Country-Jordan.pdf
      • http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHO-HAI-summary-report.pdf
      • http://www.medicinestransparency.org/news-events/article/view/information-about-medicines-where-to-start/80/
      10/06/09 MeTA
    18. Thank you!
      • Rania Bader
      • Email: raniasb2002@yahoo.com
      • Mobile number +962 79 5691921
      • MeTA: www.MedicinesTransparency.org
      10/06/09 MeTA

    + MeTApresentsMeTApresents, 5 months ago

    custom

    315 views, 0 favs, 0 embeds more stats

    A presentation describing how the Medicines Transpa more

    More info about this document

    © All Rights Reserved

    Go to text version

    • Total Views 315
      • 315 on SlideShare
      • 0 from embeds
    • Comments 0
    • Favorites 0
    • Downloads 4
    Most viewed embeds

    more

    All embeds

    less

    Flagged as inappropriate Flag as inappropriate
    Flag as inappropriate

    Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details.

    Cancel
    File a copyright complaint
    Having problems? Go to our helpdesk?

    Categories